2024年中国流式荧光行业研究报告

Investment Rating - The report does not explicitly state an investment rating for the fluorescence-activated cell sorting industry in China. Core Insights - The fluorescence-activated cell sorting technology is a novel multi-parameter diagnostic technology based on fluorescently encoded microspheres and flow principles, offering high throughput, sensitivity, and low-cost advantages compared to traditional chemiluminescence methods [2][17][24]. - The increasing demand for in vitro diagnostics driven by the rising prevalence of chronic diseases, cancer, and autoimmune diseases is expected to open up significant market opportunities for the fluorescence industry [4][60]. - Local companies with higher cost-performance products are anticipated to stand out as the industry develops, especially with the improvement of domestic R&D capabilities and favorable policies [2][5][54]. Summary by Sections Industry Overview - Flow cytometry is a low-cost, high-precision laser detection technology that allows rapid quantitative analysis of cells and particles in a sample [14][15]. - The fluorescence technology combines the flexibility and sensitivity of fluorescence with high-speed data integration, making it suitable for various applications in immunology, nucleic acid research, and enzyme analysis [18][21]. Market Size and Forecast - The Chinese fluorescence market is projected to grow from 41.2 billion RMB in 2023 to 117.5 billion RMB by 2028, with a CAGR of 23.3% [16]. - The fluorescence reagent market is expected to reach 407.8 billion RMB by 2028, driven by the increasing clinical demand for multi-parameter testing [83][87]. Competitive Landscape - The market is currently dominated by both local and international players, with local companies like Saiqi Bio leading in innovation and market penetration [98][99]. - The competitive landscape is characterized by a mix of patented technologies and independent innovations, with local firms increasingly gaining market share due to their cost advantages [95][97]. Regulatory Environment - The industry is regulated by the National Medical Products Administration (NMPA), which oversees product registration, production, and distribution [50][51]. - Recent policies are expected to enhance the R&D capabilities of local companies and promote the rapid development of the IVD industry [54][55]. Future Trends - The report highlights the potential for fluorescence technology to become a mainstream methodology in the diagnosis of immune, inflammatory, and tumor-related conditions due to its high throughput and low cost [60][63]. - The increasing focus on early diagnosis and treatment of diseases, particularly in oncology and autoimmune disorders, is expected to drive demand for fluorescence-based diagnostics [75][78].